iOrganBio, an innovator in intelligent cell manufacturing, announced the appointment of Jessica Owens to its Board of Directors. Owens brings over 20 years of experience as a venture investor and serial founder at the intersection of life sciences, health technology, and AI. She co-founded GRAIL, which raised over $1 billion and formed partnerships with Bristol Myers Squibb, Merck, and Johnson & Johnson, and serves as co-founder and General Partner at Initiate Ventures.
iOrganBio stated that Owens' counsel will be invaluable as it scales CellForge, expands partnerships, and advances AI-driven cell manufacturing to improve predictability and scalability from model development to cell therapies. The company is redefining how human cells are engineered and reliably produced at scale for research and therapeutic applications, including FDA-aligned New Approach Methodologies (NAMs).
According to the announcement, iOrganBio's CellForge platform uses AI and automation to guide cell development and make real-time adjustments aligned with defined biological profiles. At its core is the functional human CellAtlas, a comprehensive reference built from single-cell and multi-omics data that provides digital blueprints for each cell type. This closed-loop process aims to deliver accuracy, efficiency, and quality for disease modeling, regenerative medicine, and drug development.
The appointment comes as iOrganBio seeks to accelerate its growth and impact in the cell manufacturing space. For more information, visit iOrgan.Bio.
